{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:21:28Z","timestamp":1788232888171,"version":"build-2803163510"},"reference-count":27,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2022,12,22]]},"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      We present the final analysis results of the phase 2 JADE study (ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03361956\">NCT03361956<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>232 patients with chronic hepatitis B (CHB) not currently treated at study start (NCT) at study start or virologically suppressed were randomised to receive 75\u2009mg (part 1) or 250\u2009mg (part 2) JNJ-56136379, a hepatitis B virus (HBV)\u2013capsid assembly modulator, one time per day or placebo with nucleos(t)ide analogue (NA) (tenofovir disoproxil fumarate\/entecavir) or JNJ-56136379 alone (NCT-only) for \u226524\u2009and \u226448 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In patients who are NCT hepatitis B e-antigen (HBeAg) positive, JNJ-56136379 75 mg+NA\u2009and 250 mg+NA showed limited mean (SE) hepatitis B surface antigen (HBsAg) declines (0.14 (0.10) and 0.41 (0.15), respectively) from baseline at Week 24 (primary endpoint; placebo+NA: 0.25 (0.11) log\n                      <jats:sub>10<\/jats:sub>\n                      international unit (IU)\/mL).\n                    <\/jats:p>\n                    <jats:p>\n                      In patients who are NCT HBeAg positive, mean (SE) HBV DNA declines at Week 24 were 5.53 (0.23) and 5.88 (0.34) for JNJ-56136379 75 mg+NA\u2009and 250 mg+NA, respectively, versus 5.21 (0.42) log\n                      <jats:sub>10<\/jats:sub>\n                      IU\/mL for placebo+NA. In NCT patients, mean (SE) HBV RNA declines were 2.96 (0.23) and 3.15 (0.33) versus 1.33 (0.32) log\n                      <jats:sub>10<\/jats:sub>\n                      copies\/mL, respectively.\n                    <\/jats:p>\n                    <jats:p>Patients with HBsAg declines had HBeAg and hepatitis B core-related antigen (HBcrAg) declines and some early on-treatment isolated alanine aminotransferase flares. Viral breakthrough occurred with JNJ-56136379 monotherapy with the emerging resistant-variant T33N, but not with JNJ-56136379+NA. JNJ-56136379 treatment beyond Week 24 had a generally small additional effect on viral markers.<\/jats:p>\n                    <jats:p>No study treatment-related serious adverse events or clinically significant changes in laboratory parameters occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with non-cirrhotic CHB, JNJ-56136379+NA showed pronounced reductions in HBV DNA and HBV RNA, limited HBsAg or HBeAg declines in patients who are NCT HBeAg positive, and was well tolerated, but no clear benefit with regards to efficacy of JNJ-56136379 over NA was observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2022-328041","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T13:20:32Z","timestamp":1674652832000},"page":"1385-1398","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":54,"title":["Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection"],"prefix":"10.1136","volume":"72","clinical-trial-number":[{"clinical-trial-number":"nct03361956","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03361956","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Harry L A","family":"Janssen","sequence":"first","affiliation":[{"name":"Toronto General Hospital, Toronto, Ontario, Canada"},{"name":"Erasmus Medical Center, Rotterdam, Zuid-Holland, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8230-8583","authenticated-orcid":false,"given":"Jinlin","family":"Hou","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-0595","authenticated-orcid":false,"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris Cit\u00e9, INSERM UMR1149, H\u00f4pital Beaujon AP-HP, Clichy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry L Y","family":"Chan","sequence":"additional","affiliation":[{"name":"The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-0083","authenticated-orcid":false,"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon and Lyon University & INSERM U1052-Cancer Research Institute of Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kumamoto University, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Janczewska","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences in Bytom, Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald G","family":"Nahass","sequence":"additional","affiliation":[{"name":"ID Care, Hillsborough, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bourgeois","sequence":"additional","affiliation":[{"name":"ZNA Jan Palfijn, CPU, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[{"name":"Hospital Universitario Vall d'Hebr\u00f3n and CIBERHED del Instituto Carlos III, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-7476","authenticated-orcid":false,"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Department of Pathophysiology and Transplantation, CRC \u2018A. M. and A. Migliavacca\u2019 Center for Liver Disease, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Lenz","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Verbinnen","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Vandenbossche","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Talloen","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Kalmeijer","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceuticals R&D, Titusville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Beumont","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceuticals R&D, Titusville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6993-8206","authenticated-orcid":false,"given":"Michael","family":"Biermer","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Shukla","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceuticals R&D, Titusville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"2025090713145301000_72.7.1385.1","unstructured":"World Health Organization . Hepatitis B, July 27, 2021."},{"key":"2025090713145301000_72.7.1385.2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29323"},{"key":"2025090713145301000_72.7.1385.3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"2025090713145301000_72.7.1385.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"2025090713145301000_72.7.1385.5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2468-1253(19)30190-6","article-title":"Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025090713145301000_72.7.1385.6","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2025090713145301000_72.7.1385.7","doi-asserted-by":"crossref","first-page":"S771","DOI":"10.1093\/infdis\/jix355","article-title":"Toward a cure for hepatitis B virus infection: combination therapy involving viral suppression and immune modulation and long-term outcome","volume":"216","author":"Wu","year":"2017","journal-title":"J Infect Dis"},{"key":"2025090713145301000_72.7.1385.8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jhep.2020.04.013","article-title":"Hepatitis B surface antigen seroclearance: immune mechanisms, clinical impact, importance for drug development","volume":"73","author":"Tout","year":"2020","journal-title":"J Hepatol"},{"key":"2025090713145301000_72.7.1385.9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00560-17","article-title":"Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus","volume":"61","author":"Berke","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025090713145301000_72.7.1385.10","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01017-1"},{"key":"2025090713145301000_72.7.1385.11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02439-19","article-title":"Antiviral properties and mechanism of action studies of the hepatitis B virus capsid assembly modulator JNJ-56136379","volume":"64","author":"Berke","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025090713145301000_72.7.1385.12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"key":"2025090713145301000_72.7.1385.13","unstructured":"Gane EJ , Schwabe C , Lenz O . JNJ-64530440 (JNJ-0440), a novel class N capsid assembly modulator (CAM-N): safety, tolerability, pharmacokinetics (PK), and antiviral activity of multiple ascending doses in patients (PTS) with chronic hepatitis B (CHB). Hepatology 2019;70."},{"key":"2025090713145301000_72.7.1385.14","first-page":"LP1","article-title":"Continued therapy with ABI-H0731 + NrtI results in sequential reduction\/loss of HBV DNA, HBV RNA, HBeAg, HBcrAg and HBsAg in HBeA-positive patients","volume":"70","author":"Sulkowski","year":"2019","journal-title":"Hepatology"},{"key":"2025090713145301000_72.7.1385.15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","article-title":"Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial","volume":"5","author":"Yuen","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025090713145301000_72.7.1385.16","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(18)30422-7","article-title":"RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated","volume":"68","author":"Gane","year":"2018","journal-title":"J Hepatol"},{"key":"2025090713145301000_72.7.1385.17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01323-20","article-title":"A five-in-one first-in-human study to assess safety, tolerability, and pharmacokinetics of RO7049389, an inhibitor of hepatitis B virus capsid assembly, after single and multiple ascending doses in healthy participants","volume":"64","author":"Feng","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025090713145301000_72.7.1385.18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01686-19","article-title":"A first-in-human trial of GLS4, a novel inhibitor of hepatitis B virus capsid assembly, following single- and multiple-ascending-oral-dose studies with or without ritonavir in healthy adult volunteers","volume":"64","author":"Zhao","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025090713145301000_72.7.1385.19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/ciaa961","article-title":"Antiviral activity and pharmacokinetics of the hepatitis B virus (HBV) capsid assembly modulator GLS4 in patients with chronic HBV infection","volume":"73","author":"Zhang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025090713145301000_72.7.1385.20","doi-asserted-by":"crossref","unstructured":"Lam AM , Ren S , Espiritu C , et al . Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants. Antimicrob Agents Chemother 2017;61.doi:10.1128\/AAC.00680-17","DOI":"10.1128\/AAC.00680-17"},{"key":"2025090713145301000_72.7.1385.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.028"},{"key":"2025090713145301000_72.7.1385.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.06.014"},{"key":"2025090713145301000_72.7.1385.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00111-0"},{"key":"2025090713145301000_72.7.1385.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.11.030"},{"key":"2025090713145301000_72.7.1385.25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00835-18","article-title":"Novel potent capsid assembly modulators regulate multiple steps of the hepatitis B virus life cycle","volume":"62","author":"Lahlali","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025090713145301000_72.7.1385.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.08.033"},{"key":"2025090713145301000_72.7.1385.27","first-page":"820","article-title":"Analysis of the longer-term safety profile of the hepatitis B virus core inhibitor ABI-H0731 in an open-label extension study","volume":"72","author":"Jacobson","year":"2020","journal-title":"Hepatology"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2022-328041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T20:15:02Z","timestamp":1757276102000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2022-328041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,6,7]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1136\/gutjnl-2022-328041"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2022-328041","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]}}}